527 related articles for article (PubMed ID: 18692036)
1. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M
Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
3. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients.
Anraku M; Kitamura K; Shinohara A; Adachi M; Suenga A; Maruyama T; Miyanaka K; Miyoshi T; Shiraishi N; Nonoguchi H; Otagiri M; Tomita K
Kidney Int; 2004 Aug; 66(2):841-8. PubMed ID: 15253741
[TBL] [Abstract][Full Text] [Related]
4. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
Sezer MT; Akin H; Demir M; Erturk J; Aydin ZD; Savik E; Tunc N
J Nephrol; 2007; 20(2):196-203. PubMed ID: 17514624
[TBL] [Abstract][Full Text] [Related]
5. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
6. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
8. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients.
Kalantar-Zadeh K; Don BR; Rodriguez RA; Humphreys MH
Am J Kidney Dis; 2001 Mar; 37(3):564-72. PubMed ID: 11228181
[TBL] [Abstract][Full Text] [Related]
9. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
10. Importance of iron supply for erythropoietin therapy.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
[TBL] [Abstract][Full Text] [Related]
11. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
13. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
Saltissi D; Sauvage D; Westhuyzen J
Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
[TBL] [Abstract][Full Text] [Related]
14. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
15. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation.
Tovbin D; Mazor D; Vorobiov M; Chaimovitz C; Meyerstein N
Am J Kidney Dis; 2002 Nov; 40(5):1005-12. PubMed ID: 12407646
[TBL] [Abstract][Full Text] [Related]
16. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients.
Fusaro M; Munaretto G; Spinello M; Rebeschini M; Amici G; Gallieni M; Piccoli A
J Nephrol; 2005; 18(1):72-9. PubMed ID: 15772926
[TBL] [Abstract][Full Text] [Related]
17. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress and ferritin levels in haemodialysis patients.
Senol E; Ersoy A; Erdinc S; Sarandol E; Yurtkuran M
Nephrol Dial Transplant; 2008 Feb; 23(2):665-72. PubMed ID: 18039638
[TBL] [Abstract][Full Text] [Related]
19. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
20. Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study.
Szklarek-Kubicka M; Fijałkowska-Morawska J; Zaremba-Drobnik D; Uciński A; Czekalski S; Nowicki M
J Ren Nutr; 2009 Nov; 19(6):487-93. PubMed ID: 19616450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
